ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
31 announcements
QMS Medical Allied Services Limited held its 9th Annual General Meeting on September 30, 2026. Shareholders approved a 5% final dividend and adoption of financial results.
QMS Medical Allied Services Limited is acquiring BeamOptics Scientific Private Limited. The strategic acquisition aims to expand the company's addressable market in healthcare business.
QMS Medical Allied Services executed a shareholders' agreement with investors and its subsidiary, Saarathi Healthcare, defining governance rights, veto powers, and share transfer restrictions.
QMS Medical Allied Services Limited approved a composite demerger scheme for its healthcare business and the acquisition of a 100% stake in BeamOptics Scientific Private Limited.
QMS Medical Allied Services Ltd acquired the remaining 24% stake in Saarathi Healthcare Private Limited for Rs. 14.23 Crore, making it a wholly-owned subsidiary.
QMS Medical Allied Services Limited informed the exchange regarding the dispatch of annual report links to shareholders who haven't registered their email addresses.
QMS Medical Allied Services Limited has filed its Annual Report for the financial year 2025-26. The 9th Annual General Meeting is scheduled for September 30, 2026.
QMS Medical Allied Services Limited issued the notice for its 9th Annual General Meeting scheduled for September 30, 2026.
QMS Medical Allied Services Limited has appointed Mr. Pranav Manhar Badheka as a Non-Executive Independent Director, effective September 3, 2026, for a five-year term.
QMS Medical Allied Services appointed Mr. Pranav Manhar Badheka as an Independent Director and approved the draft notice for the upcoming 9th Annual General Meeting.
QMS Medical Allied Services secured exclusive Indian marketing and distribution rights for HEINE Optotechnik's diagnostic instruments. The five-year agreement targets revenues of Rs. 70 crore by 2031.
Q1 FY27 saw 22% YoY revenue growth driven by service expansion. Successful migration to NSE main board and planned 100% acquisition of Saarathi Healthcare highlight strategic scale-up in Patient Support Programs (PSP).
QMS Medical Allied Services Ltd achieved a "Gold" certification in a cybersecurity assessment by CyberVadis. The company scored 918/1000, valid until August 2027.
QMS delivered strong Q1FY27 performance with 22% YoY revenue growth. Strategy focuses on scaling Services (Patient Support Programs) and expanding proprietary Q-Devices portfolio.
QMS Medical Allied Services Ltd reported revenue from operations of ₹56.9 Cr (+22.4% YoY) and net profit of ₹4 Cr (+25.0% YoY) for Q1 FY27.
QMS Medical Allied Services Limited will hold a board meeting on 14-Aug-2026 to consider and approve its unaudited quarterly financial results for June 2026.
QMS Medical Allied Services Limited announced that its subsidiary, Saarathi Healthcare Private Limited, has received a SOC 2 Type II certificate for its information security controls.
QMS Medical Allied Services received NSE approval to migrate from SME Emerge to the Main Board. Trading on the main board begins June 18, 2026, enhancing visibility and liquidity.
QMS Medical Allied Services delivered ₹172.9cr revenue (11% YoY growth) in FY26, driven by a shift toward high-margin patient support services despite margin compression from strategic front-loaded investments.
QMS Medical corrected a typographical date error in its FY26 financial results. The clerical update does not impact the previously reported financial figures or audit opinion.
QMS reports FY26 revenue of ₹172.9 Cr, up 11% YoY, driven by services expansion and the Saarathi Healthcare integration. The company is pivoting towards high-growth Patient Support Programs (PSP).
QMS Medical Allied Services received in-principle approval to migrate from NSE EMERGE to the Main Board. This transition enhances the company's market visibility and liquidity.
QMS Medical Allied Services Limited recommended a final dividend of ₹0.05 per equity share. The record date for the payout will be fixed during the General Meeting.
QMS Medical Allied Services reported zero deviation in utilizing ₹12.05 Crore raised via its Rights Issue. Funds were fully deployed for subsidiary acquisition and corporate purposes.
QMS Medical Allied Services Ltd reported revenue from operations of ₹44.4 Cr (-0.4% YoY) and net profit of ₹2 Cr (-44.4% YoY) for Q4 FY26.
QMS Medical Allied Services approved its FY26 audited financial results and recommended a Rs. 0.50 dividend per share. The company also approved migration to the NSE Main Board.
QMS Medical Allied Services Limited will hold a board meeting on May 30, 2026. Directors will consider annual audited financial results and a final dividend recommendation.
QMS Medical Allied Services Limited submitted its annual SDD Compliance Certificate for FY2026. The filing confirms full compliance with SEBI insider trading database regulations.
QMS Medical Allied Services Limited submitted its monitoring report for the ₹12.05 Crore Rights Issue. CARE Ratings confirmed no deviations in fund utilization during the quarter.
QMS Medical Allied Services Limited informed the National Stock Exchange that it does not meet the SEBI criteria for 'Large Corporate' classification for FY 2025-26. Consequently, the company is not required to submit annual disclosures under the Large Corporate borrowing framework.